Top

Published in:

Open Access 01-02-2015 | Review

GH and the cardiovascular system: an update on a topic at heart

Authors: Jörgen Isgaard, Michele Arcopinto, Kristjan Karason, Antonio Cittadini

Published in: Endocrine | Issue 1/2015

Abstract

In this review, the importance of growth hormone (GH) for the maintenance of normal cardiac function in adult life is discussed. Physiological effects of GH and underlying mechanisms for interactions between GH and insulin-like growth factor I (IGF-I) and the cardiovascular system are covered as well as the cardiac dysfunction caused both by GH excess (acromegaly) and by GH deficiency in adult hypopituitary patients. In both acromegaly and adult GH deficiency, there is also increased cardiovascular morbidity and mortality possibly linked to aberrations in GH status. Finally, the status of the GH/IGF-I system in relation to heart failure and the potential of GH as a therapeutic tool in the treatment of heart failure are reviewed in this article.

L. Sacca, A. Cittadini, S. Fazio, Growth hormone and the heart. Endocr. Rev. 15, 555–573 (1994)PubMed

J. Ren, W.K. Samson, J.R. Sowers, Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J. Mol. Cell. Cardiol. 31, 2049–2061 (1999)PubMed

Y. Sverrisdóttir, M. Elam, B.-Å. Bengtsson, G. Johannsson, Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency. J. Clin. Endocrinol. Metab. 83, 1881–1885 (1998)PubMed

J. Isgaard, A. Nilsson, K. Vikman, O.G. Isaksson, Growth hormone regulates the level of insulin-like growth factor-I mRNA in rat skeletal muscle. J. Endocrinol. 120, 107–112 (1989)PubMed

A.J. D’Ercole, A.D. Stiles, L.E. Underwood, Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc. Natl. Acad. Sci. USA 81, 935–939 (1984)PubMedCentralPubMed

P. Delafontaine, K.E. Bernstein, R.W. Alexander, Insulin-like growth factor I gene expression in vascular cells. Hypertension 17, 693–699 (1991)PubMed

L.S. Mathews, B. Enberg, G. Norstedt, Regulation of rat growth hormone receptor gene expression. J. Biol. Chem. 264, 9905–9910 (1989)PubMed

J. Isgaard, H. Wåhlander, M.A. Adams, P. Friberg, Increased expression of growth hormone receptor mRNA and insulin-like growth factor-I mRNA in volume-overloaded hearts. Hypertension 23, 884–888 (1994)PubMed

A. Wickman, P. Friberg, M.A. Adams, G.L. Matejka, C. Brantsing, G. Guron, J. Isgaard, Induction of growth hormone receptor and insulin-like growth factor-I mRNA in aorta and caval vein during hemodynamic challenge. Hypertension 29, 123–130 (1997)PubMed

10.

H.P. Guler, J. Zapf, E. Scheiwiller, E.R. Froesch, Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats. Proc. Natl. Acad. Sci. USA 85, 4889–4893 (1988)PubMedCentralPubMed

11.

A. Wickman, J. Isgaard, M.A. Adams, P. Friberg, Inhibition of nitric oxide in rats. Regulation of cardiovascular structure and expression of insulin-like growth factor I and its receptor messenger RNA. J. Hypertens. 15, 751–759 (1997)PubMed

12.

G. Pete, Y. Hu, M. Walsh, J. Sowers, J.C. Dunbar, Insulin-like growth factor-I decreases mean blood pressure and selectively increases regional blood flow in normal rats. Proc. Soc. Exp. Biol. Med. 213, 187–192 (1996)PubMed

13.

M.F. Walsh, M. Barazi, G. Pete, R. Muniyappa, J.C. Dunbar, J.R. Sowers, Insulin-like growth factor I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology 137, 1798–1803 (1996)PubMed

14.

M.Y. Donath, R. Jenni, H.P. Brunner, M. Anrig, S. Kohli, Y. Glatz, E.R. Froesch, Cardiovascular and metabolic effects of insulin-like growth factor I at rest and during exercise in humans. J. Clin. Endocrinol. Metab. 81, 4089–4094 (1996)PubMed

15.

M.Y. Donath, G. Sutsch, X.W. Yan, B. Piva, H.P. Brunner, Y. Glatz, J. Zapf, F. Follath, E.R. Froesch, W. Kiowski, Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure. J. Clin. Endocrinol. Metab. 83, 3177–3183 (1998)PubMed

16.

F. Manelli, M. Volterrani, R. Lorusso, G. Romanelli, A. Giustina, Acute growth hormone effects in human subjects with heart failure, in Growth Hormone and the Heart, ed. by A. Giustina (Kluwer Academic, Boston, 2001), pp. 87–96

17.

R. Napoli, V. Guardasole, V. Angelini, F. D´Amico, E. Zarra, M. Matarazzo, L. Saccà, Acute effects of growth hormone on vascular function in human subjects. J. Clin. Endocrinol. Metab. 88, 2817–2820 (2003)PubMed

18.

G. Lembo, H.A. Rockman, J.J. Hunter, H. Steinmetz, W.J. Koch, L. Ma, M.P. Prinz, J. Ross Jr, K.R. Chien, L. Powell-Braxton, Elevated blood pressure and enhanced myocardial contractility in mice with severe IGF-1 deficiency. J. Clin. Invest. 98, 2648–2655 (1996)PubMedCentralPubMed

19.

Å. Tivesten, E. Bollano, I. Andersson, S. Fitzgerald, K. Caidahl, K. Sjögren, O. Skøtt, J.-L. Liu, D. LeRoith, R. Mobini, O.G.P. Isaksson, J.-O. Jansson, C. Ohlsson, G. Bergström, J. Isgaard, Liver-derived insulin-like growth factor-I is involved in the regulation of blood pressure in nice. Endocrinology 143, 4235–4242 (2002)PubMed

20.

H. Tsukahara, D.V. Gordienko, B. Tonshoff, M.C. Gelato, M.S. Goligorsky, Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int. 45, 598–604 (1994)PubMed

21.

R. Muniyappa, M.F. Walsh, J.S. Rangi, R.M. Zayas, P.R. Standley, J.L. Ram, J.R. Sowers, Insulin like growth factor 1 increases vascular smooth muscle nitric oxide production. Life Sci. 61, 925–931 (1997)PubMed

22.

J. Haylor, I. Singh, A.M. el Nahas, Nitric oxide synthesis inhibitor prevents vasodilation by insulin-like growth factor I. Kidney Int. 39, 333–335 (1991)PubMed

23.

D.A. Fryburg, NG-monomethyl-l-arginine inhibits the blood flow but not the insulin-like response of forearm muscle to IGF- I: possible role of nitric oxide in muscle protein synthesis. J. Clin. Invest. 97, 1319–1328 (1996)PubMedCentralPubMed

24.

C.L. Oltman, N.L. Kane, D.D. Gutterman, R.S. Bar, K.C. Dellsperger, Mechanism of coronary vasodilation to insulin and insulin-like growth factor I is dependent on vessel size. Am. J. Physiol. Endocrinol. Metab. 279, E176–E181 (2000)PubMed

25.

R. Hirschberg, J.D. Kopple, Evidence that insulin-like growth factor I increases renal plasma flow and glomerular filtration rate in fasted rats. J. Clin. Invest. 83, 326–330 (1989)PubMedCentralPubMed

26.

D. Hasdai, R.A. Rizza, D.R. Holmes Jr, D.M. Richardson, P. Cohen, A. Lerman, Insulin and insulin-like growth factor-I cause coronary vasorelaxation in vitro. Hypertension 32, 228–234 (1998)PubMed

27.

P.R. Standley, F. Zhang, R.M. Zayas, R. Muniyappa, M.F. Walsh, E. Cragoe, J.R. Sowers, IGF-I regulation of Na(+)-K(+)-ATPase in rat arterial smooth muscle. Am. J. Physiol. 273, E113–E121 (1997)PubMed

28.

Å. Tivesten, A. Barlind, K. Caidahl, N. Klintland, A. Cittadini, C. Ohlsson, J. Isgaard, J. Endocrinol. 183, 195–202 (2004)PubMed

29.

A. Fujita, Y. Kurachi, Molecular aspects of ATP sensitive K⁺ channels in the cardiovascular system and K⁺ channel openers. Pharmacol. Ther. 85, 39–53 (2000)PubMed

30.

T. Miki, M. Suzuki, T. Shibasaki, H. Uemura, T. Sato, K. Yamaguchi, H. Koseki, T. Iwanaga, H. Nakaya, S. Seino, Mouse model of prinzmetal angina by disruption of the inward rectifier Kir6^.1. Nat. Med. 8, 466–472 (2002)PubMed

31.

Y. Sverrisdottir, M. Elam, K. Caidahl, A.S. Söderling, H. Herlitz, G. Johannsson, The effect of growth hormone (GH) replacement therapy on sympathetic nerve hyperactivity in hypopituitary adults: a double-blind, placebo-controlled, crossover, short-term trial followed by long-term open GH replacement in hypopituitary adults. J. Hypertens. 10, 1905–1914 (2003)

32.

T. Rosén, S. Edén, G. Larsson, L. Wilhelmsen, B.-Å. Bengtsson, Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol. 129, 195–200 (1993)PubMed

33.

V. Markussis, S. Beshyah, C. Fisher, P. Sharp, A. Nicolaides, D. Johnston, Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet 340, 1188–1192 (1992)PubMed

34.

A. Cittadini, A. Cuocolo, B. Merola, S. Fazio, D. Sabatini, E. Nicolai, A. Colao, S. Longobardi, G. Lombardi, L. Sacca, Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement. Am. J. Physiol. 267, E219–E225 (1994)PubMed

35.

G. Amato, C. Carella, S. Fazio, G. La Montagna, A. Cittadini, D. Sabatini, C. Marciano-Mone, L. Sacca, A. Bellastella, Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J. Clin. Endocrinol. Metab. 77, 1671–1676 (1993)PubMed

36.

S. Fazio, A. Cittadini, D. Sabatini, B. Merola, A. Colao, B. Biondi, S. Longobardi, G. Lombardi, L. Sacca, Growth hormone and heart performance. A novel mechanism of cardiac wall stress regulation in humans. Eur. Heart J. 18, 340–347 (1997)PubMed

37.

K. Caidahl, S. Edén, B.-Å. Bengtsson, Cardiovascular and renal effects of growth hormone. Clin. Endocrinol. 40, 93–400 (1994)

38.

G. Johannsson, P. Mårin, L. Lönn, M. Ottosson, K. Stenlöf, P. Björntorp, L. Sjöström, B.-Å. Bengtsson, GH treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J. Clin. Endocrinol. Metab. 82, 727–734 (1997)PubMed

39.

R. Böger, C. Skamira, S. Bode-Böger, G. Brabant, A. von zur Mühlen, J. Frölich, Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. J. Clin. Invest. 98, 2706–2713 (1996)PubMedCentralPubMed

40.

G. Götherström, J. Svensson, J. Koranyi, M. Alpsten, I. Bosæus, B.-Å. Bengtsson, G. Johannsson, A prospective study of five years of growth hormone (GH) replacement therapy in GH deficient adults; sustained effects on body composition, bone mass, and metabolic indices. J. Clin. Endocrinol. Metab. 86, 4657–4665 (2001)PubMed

41.

J. ter Maaten, H. de Boer, O. Kamp, L. Stuurman, E. van der Veen, Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency. J. Clin. Endocrinol. Metab. 84, 2373–2380 (1999)PubMed

42.

G. Johannsson, K. Sunnerhagen, J. Svensson, Baseline characteristics and the effects of two years of growth hormone (GH) replacement therapy in adults with GH deficiency previously treated for Cushing´s disease. Clin. Endocrinol. 60, 550–559 (2004)

43.

F. Borson-Chazot, A. Serusclat, Y. Kalfallah, X. Ducottet, G. Sassolas, S. Bernard, F. Labrousse, J. Pastene, A. Sassolas, Y. Roux, F. Berthezene, Decrease in carotid intima-media thickness after one year growth hormone (GH) treatment in adults with GH deficiency. J. Clin. Endocrinol. Metab. 84, 1329–1333 (1999)PubMed

44.

M. Pfeifer, M. Verhovec, B. Zizek, J. Prezelj, P. Poredos, R.N. Clayton, Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J. Clin. Endocrinol. Metab. 84, 453–457 (1999)PubMed

45.

D.G. Penney, J.C. Dunbar Jr, M.S. Baylerian, Cardiomegaly and haemodynamics in rats with a transplantable growth hormone-secreting tumour. Cardiovasc. Res. 19, 270–277 (1985)PubMed

46.

Y.M. Bohlooly, L. Carlson, B. Olsson, H. Gustafsson, I.J. Andersson, J. Törnell, G. Bergström, Vascular function and blood pressure in GH transgenic mice. Endocrinology 142, 3317–3323 (2001)

47.

M. Losa, K. von Werder, The heart in acromegaly, in Growth Hormone and the Heart, ed. by A. Giustina (Kluwer Academic, Boston, 2001), pp. 33–43

48.

S. Mosca, S. Paolillo, A. Colao, E. Bossone, A. Cittadini, F.L. Ludice, A. Parente, S. Conte, G. Rengo, D. Leosco, B. Trimarco, P.P. Filardi, Cardiovascular involvement in patients affected by acromegaly: an appraisal. Int. J. Cardiol. 167, 1712–1718 (2013)PubMed

49.

F. Bogazzi, L. Battolla, C. Spinelli, G. Rossi, S. Gavioli, V. Di Bello, C. Cosci, C. Sardella, D. Volterrani, E. Talini, P. Pepe, F. Falaschi, G. Mariani, E. Martino, Risk factors for development of coronary artery disease in patients with acromegaly: a five-year prospective study. J. Clin. Endocrinol. Metab. 92, 4271–4277 (2007)PubMed

50.

H. Akutsu, J. Kreutzer, G. Wasmeier, D. Ropers, C. Rost, M. Möhlig, H. Wallaschofski, M. Buchfelder, C. Schöfl, Acromegaly per se does not increase the risk for coronary artery disease. Eur. J. Endocrinol. 162, 879–886 (2010)PubMed

51.

M. Otsuki, S. Kasayama, H. Yamamoto, H. Saito, S. Sumitani, H. Kouhara, Y. Saitoh, T. Ohnishi, N. Arita, Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clin. Endocrinol. 54, 791–796 (2001)

52.

J. Verhelst, B. Velkeniers, D. Maiter, P. Haentjens, G. T´Sjoen, G. Rietzschel, B. Corvilain, P. Abrams, F. Nobels, R. Abs, M. Bex, Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly. Eur. J. Endocrinol. 168, 177–184 (2013)PubMed

53.

M.Y. Donath, J. Zapf, M. Eppenberger-Eberhardt, E.R. Froesch, H.M. Eppenberger, Insulin-like growth factor I stimulates myofibril development and decreases smooth muscle alpha-actin of adult cardiomyocytes. Proc. Natl. Acad. Sci. USA 91, 1686–1690 (1994)PubMedCentralPubMed

54.

H. Ito, M. Hiroe, Y. Hirata, M. Tsujino, S. Adachi, M. Shichiri, A. Koike, A. Nogami, F. Marumo, Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 87, 1715–1721 (1993)PubMed

55.

P. Schnabel, F. Mies, T. Nohr, M. Geisler, M. Bohm, Differential regulation of phospholipase C-beta isozymes in cardiomyocyte hypertrophy. Biochem. Biophys. Res. Commun. 275, 1–6 (2000)PubMed

56.

C. Lu, G. Schwartzbauer, M.A. Sperling, S.U. Devaskar, S. Thamotharan, P.D. Robbins, C.F. McTiernan, J.L. Liu, J. Jiang, S.J. Frank, R.K. Menon, Demonstration of direct effects of growth hormone on neonatal cardiomyocytes. J. Biol. Chem. 276, 22892–22900 (2001)PubMed

57.

S.J. Fuller, J.R. Mynett, P.H. Sugden, Stimulation of cardiac protein synthesis by insulin-like growth factors. Biochem. J. 282(Pt 1), 85–90 (1992)PubMedCentralPubMed

58.

M.Y. Donath, M.A. Gosteli-Peter, C. Hauri, E.R. Froesch, J. Zapf, Insulin-like growth factor-I stimulates myofibrillar genes and modulates atrial natriuretic factor mRNA in rat heart. Eur. J. Endocrinol. 137, 309–315 (1997)PubMed

59.

A. Musaro, K.J. McCullagh, F.J. Naya, E.N. Olson, N. Rosenthal, IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature 400, 581–585 (1999)PubMed

60.

E.E. Creemers, J.P. Cleutjens, J.F. Smits, M.J. Daemen, Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ. Res. 89, 201–210 (2001)PubMed

61.

R.P. Butt, G.J. Laurent, J.E. Bishop, Collagen production and replication by cardiac fibroblasts is enhanced in response to diverse classes of growth factors. Eur. J. Cell Biol. 68, 330–335 (1995)PubMed

62.

A. Bruel, H. Oxlund, Biosynthetic growth hormone increases the collagen deposition rate in rat aorta and heart. Eur. J. Endocrinol. 132, 195–199 (1995)PubMed

63.

A. Cittadini, H. Stromer, S.E. Katz, R. Clark, A.C. Moses, J.P. Morgan, P.S. Douglas, Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation. Circulation 93, 800–809 (1996)PubMed

64.

A. Bruel, H. Oxlund, J.R. Nyengaard, Growth hormone increases the total number of myocyte nuclei in the left ventricle of adult rats. Growth Horm. IGF Res. 12, 106–115 (2002)PubMed

65.

J. Kajstura, W. Cheng, R. Sarangarajan, P. Li, B. Li, J.A. Nitahara, S. Chapnick, K. Reiss, G. Olivetti, P. Anversa, Necrotic and apoptotic myocyte cell death in the aging heart of Fischer 344 rats. Am. J. Physiol. 271, H1215–H1228 (1996)PubMed

66.

Q. Li, B. Li, X. Wang, A. Leri, K.P. Jana, Y. Liu, J. Kajstura, R. Baserga, P. Anversa, Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertophy. J. Clin. Invest. 100, 1991–1999 (1997)PubMedCentralPubMed

67.

M. Buerke, T. Murohara, C. Skurk, C. Nuss, K. Tomaselli, A.M. Lefer, Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc. Natl. Acad. Sci. USA 92, 8031–8035 (1995)PubMedCentralPubMed

68.

K. Reiss, W. Cheng, A. Ferber, J. Kajstura, P. Li, B. Li, G. Olivetti, C.J. Homcy, R. Baserga, P. Anversa, Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice. Proc. Natl. Acad. Sci. USA 93, 8630–8635 (1996)PubMedCentralPubMed

69.

S. Longobardi, A. Cuocolo, B. Merola, F. Di Rella, A. Colao, E. Nicolai, S. Cardei, M. Salvatore, G. Lombardi, Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency. Clin. Endocrinol. 48, 137–143 (1998)

70.

R. Cuneo, F. Salomon, C. Wiles, R. Hesp, P. Sönksen, Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance. J. Appl. Physiol. 70, 695–700 (1991)PubMed

71.

S. Beshyah, M. Shahi, E. Skinner, P. Sharp, R. Foale, D. Johnston, Cardiovascular effects of growth hormone replacement therapy in hypopituitary adults. Eur. J. Endocrinol. 130, 451–458 (1994)PubMed

72.

S. Fort, J. Weaver, J. Monson, P. Mills, The effects of low dose recombinant human growth hormone on cardiovascular structure and function in hypopituitary adults growth hormone-deficient adults. Endocrinol. Metab. 2, 119–126 (1995)

73.

L. Thuesen, J. Jørgensen, J. Müller, B. Kristensen, N. Skakkebæk, N. Vahl, J.S. Christiansen, Short and long-term cardiovascular effects of growth hormone therapy in growth hormone deficient adults. Clin. Endocrinol. 41, 615–620 (1994)

74.

G. Johannsson, B.-Å. Bengtsson, B. Andersson, J. Isgaard, K. Caidahl, Long-term cardiovascular effects of growth hormone treatment in GH-deficient adults. Preliminary data in a small group of patients. Clin. Endocrinol. 45, 305–314 (1996)

75.

L. Saccà, R. Napoli, A. Cittadini, Growth hormone, acromegaly and heart failure: an intricate triangulation. Clin. Endocrinol. 59, 660–671 (2003)

76.

E. Bollano, E. Omerovic, M. Bohlooly-y, V. Kujacic, B. Madhu, J. Tornell, O. Isaksson, B. Soussi, W. Schulze, M.L. Fu, G. Matejka, F. Waagstein, J. Isgaard, Impairment of cardiac function and bioenergetics in adult transgenic mice overexpressing the bovine growth hormone gene. Endocrinology 141, 2229–2235 (2000)PubMed

77.

U. Vetter, C. Kupferschmid, D. Lang, S. Pentz, Insulin-like growth factors and insulin increase the contractility of neonatal rat cardiocytes in vitro. Basic Res. Cardiol. 83, 647–654 (1988)PubMed

78.

N.S. Freestone, S. Ribaric, W.T. Mason, The effect of insulin-like growth factor-1 on adult rat cardiac contractility. Mol. Cell. Biochem. 163–164, 223–229 (1996)PubMed

79.

A. Cittadini, Y. Ishiguro, H. Strömer, M. Spindler, A.C. Moses, R. Clark, P.S. Douglas, J.S. Ingwall, J.P. Morgan, Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca²⁺ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles. Circ. Res. 83, 50–59 (1998)PubMed

80.

H. Strömer, A. Cittadini, P.S. Douglas, J.P. Morgan, Exogenously administered growth hormone and insulin-like growth factor-I alter intracellular Ca²⁺ handling and enhance cardiac performance. In vitro evaluation in the isolated isovolumic buffer-perfused rat heart. Circ. Res. 79, 227–236 (1996)PubMed

81.

M. Tajima, E.O. Weinberg, J. Bartunek, H. Jin, R. Yang, N.F. Paoni, B.H. Lorell, Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure. Circulation 99, 127–134 (1999)PubMed

82.

A. Cittadini, H. Strömer, D.E. Vatner, J.D. Grossman, S.E. Katz, R. Clark, J.P. Morgan, P.S. Douglas, Consequences of growth hormone deficiency on cardiac structure, function, and beta-adrenergic pathway: studies in mutant dwarf rats. Endocrinology 138, 5161–5169 (1997)PubMed

83.

H. Strömer, A. Cittadini, J.D. Grossman, P.S. Douglas, J.P. Morgan, Intrinsic cardiac muscle function, calcium handling and beta -adrenergic responsiveness is impaired in rats with growth hormone deficiency. Growth Horm. IGF Res. 1999(9), 262–271 (1999)

84.

J. Ren, H. Brown-Borg, Impaired cardiac excitation-contraction coupling in ventricular myocytes from Ames dwarf mice with IGF-I deficiency. Growth Horm. IGF Res. 12, 99–105 (2002)PubMed

85.

S. Kinugawa, H. Tsutsui, T. Ide, R. Nakamura, K. Arimura, K. Egashira, A. Takeshita, Positive inotropic effect of insulin-like growth factor-1 on normal and failing cardiac myocytes. Cardiovasc. Res. 43, 157–164 (1999)PubMed

86.

M.L. Solem, A.P. Thomas, Modulation of cardiac Ca²⁺ channels by IGF-1. Biochem. Biophys. Res. Commun. 252, 151–155 (1998)PubMed

87.

X.P. Xu, P.M. Best, Decreased transient outward K⁺ current in ventricular myocytes from acromegalic rats. Am. J. Physiol. 260, H935–H942 (1991)PubMed

88.

W.V. Houck, L.C. Pan, S.B. Kribbs, M.J. Clair, G.M. McDaniel, R.S. Krombach, W.M. Merritt, C. Pirie, J.P. Iannini, R. Mukherjee, F.G. Spinale, Effects of growth hormone supplementation on left ventricular morphology and myocyte function with the development of congestive heart failure. Circulation 100, 2003–2009 (1999)PubMed

89.

H. Jin, R. Yang, H. Lu, A.K. Ogasawara, W. Li, A. Ryan, F. Peale, N.F. Paoni, Effects of early treatment with growth hormone on infarct size, survival, and cardiac gene expression after acute myocardial infarction. Growth Horm. IGF Res. 12, 208–215 (2002)PubMed

90.

T. Ueyama, T. Ohkusa, M. Yano, M. Matsuzaki, Growth hormone preserves cardiac sarcoplasmic reticulum Ca²⁺ release channels (ryanodine receptors) and enhances cardiac function in cardiomyopathic hamsters. Cardiovasc. Res. 40, 64–73 (1998)PubMed

91.

E. Mayoux, R. Ventura-Clapier, J. Timsit, F. Behar-Cohen, C. Hoffmann, J.J. Mercadier, Mechanical properties of rat cardiac skinned fibers are altered by chronic growth hormone hypersecretion. Circ. Res. 72, 57–64 (1993)PubMed

92.

J. Timsit, B. Riou, J. Bertherat, C. Wisnewsky, N.S. Kato, A.S. Weisberg, J. Lubetzki, Y. Lecarpentier, S. Winegrad, J.J. Mercadier, Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern, and myosin adenosine triphosphatase activity of rat left ventricle. J. Clin. Invest. 86, 507–515 (1990)PubMedCentralPubMed

93.

J.-O. Johansson, J. Fowelin, K. Landin, I. Lager, B.-Å. Bengtsson, Growth hormone-deficient adults are insulin-resistant. Metabolism 44, 1126–1129 (1995)PubMed

94.

F. Hew, M. Koschmann, M. Christopher, C. Rantzau, A. Vaag, G. Ward, H. Beck-Nielsen, F. Alford, Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity. J. Clin. Endocrinol. Metab. 81, 555–564 (1996)PubMed

95.

W. Drake, S. Howell, J. Monson, S. Shalet, Optimizing GH therapy in adults and children. Endocr. Rev. 22, 425–450 (2001)PubMed

96.

J.-O. Johansson, K. Landin, L. Tengborn, T. Rosén, B.-Å. Bengtsson, High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler. Thromb. 14, 434–437 (1994)PubMed

97.

M. Gola, S. Bonadonna, M. Doga, A. Giustina, Clinical review. Growth hormone and cardiovascular risk factors. J. Clin. Endocrinol. Metab. 90(3), 1864–1870 (2005)PubMed

98.

L. Li, W. Ren, J. Li, Increase in serum pregnancy-associated plasma protein-A is correlated with increase in cardiovascular risk factors in adult patients with growth hormone deficiency. Endocrine 42(2), 375–381 (2012)PubMed

99.

T. Rosén, I. Bosaeus, J. Tölli, G. Lindstedt, B.-Å. Bengtsson, Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency. Clin. Endocrinol. 38, 63–71 (1993)

100.

A. Juul, N. Hjortskov, L. Jepsen, B. Nielsen, J. Halkjaer-Kristensen, N. Vahl, J.O. Jørgensen, J.S. Christiansen, N. Skakkebaek, Growth hormone deficiency and hyperthermia during exercise: a controlled study of sixteen GH-deficient patients. J. Clin. Endocrinol. Metab. 80, 3335–3340 (1995)PubMed

101.

C. Gazzaruso, M. Gola, I. Karamouzis, R. Giubbini, A. Giustina, Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH: an update. J. Clin. Endocrinol. Metab. 99(1), 18–29 (2014)PubMed

102.

M. Elbornsson, G. Götherström, I. Bosaeus, B.-Å. Bengtsson, G. Johannsson, J. Svensson, Fifteen years of growth hormone replacement improves body composition and cardiovascular risk factors. Eur. J. Endocrinol. 168, 745–753 (2013)PubMedCentralPubMed

103.

J.-O. Johansson, K. Landin, G. Johannsson, L. Tengborn, B.-Å. Bengtsson, Long-term treatment with growth hormone decreases plasminogen activator inhibator-I and tissue plasminogen activator in growth hormone-deficient adults. Thromb. Haemost. 76, 422–428 (1996)PubMed

104.

M. Christopher, F. Hew, M. Oakley, C. Rantzau, F. Alford, Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy. J. Clin. Endocrinol. Metab. 83, 1668–1681 (1998)PubMed

105.

J. Svensson, J. Fowelin, K. Landin, B.-Å. Bengtsson, J.-O. Johansson, Effects of 7 years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J. Clin. Endocrinol. Metab. 87, 2121–2127 (2002)PubMed

106.

B. Bülow, L. Hagmar, Z. Mikoczy, C. Nordström, E. Erfurth, Increased cerebrovascular mortality in patients with hypopituitarism. Clin. Endocrinol. 46, 75–81 (1997)

107.

A. Bates, W. Van´t Hoff, P. Jones, R. Clayton, The effect of hypopituitarism on life expectancy. J. Clin. Endocrinol. Metab. 81, 1169–1172 (1996)PubMed

108.

J. Tomlinson, N. Holden, R. Hills, K. Wheatley, R. Clayton, A. Bates, M. Sheppard, P. Stewart, Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357, 425–431 (2001)PubMed

109.

J. Svensson, B.-Å. Bengtsson, T. Rosén, A. Odén, G. Johannson, The incidence of malignant disease and cardiovascular morbidity in hypopituitary patients with or without growth hormone replacement therapy. J. Clin. Endocrinol. Metab. 89, 3306–3312 (2004)PubMed

110.

M. Hartman, R. Xu, B.J. Crowe, L.L. Robison, E.M. Erfurth, D.L. Kleinberg, A.G. Zimmermann, W.W. Woodmansee, G.B. Cutler Jr, J.J. Chipman, S.S. Melmed, International HypoCCS Advisory Board: prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. J. Clin. Endocrinol. Metab. 98, 980–988 (2013)PubMedCentralPubMed

111.

R. Yang, S. Bunting, N. Gillett, R. Clark, H. Jin, Growth hormone improves cardiac performance in experimental heart failure. Circulation 92, 262–267 (1995)PubMed

112.

J. Isgaard, V. Kujacic, E. Jennische, A. Holmäng, X.Y. Sun, T. Hedner, Å. Hjalmarson, B.-Å. Bengtsson, Growth hormone improves cardiac function in rats with experimental myocardial infarction. Eur. J. Clin. Invest. 27, 517–525 (1997)PubMed

113.

H. Jin, R. Yang, N. Gillett, R.G. Clark, A. Ko, N.F. Paoni, Beneficial effects of growth hormone and insulin-like factor-1 in experimental heart failure in rats treated with chronic ACE inhibition. J. Cardiovasc. Pharmacol. 26, 420–425 (1995)PubMed

114.

E. Omerovic, R. Fahrami, M. Basetti, B. Soussi, Å. Hjalmarson, F. Waagstein, J. Isgaard, Growth hormone improves bioenergetics and decreases catecholamines in postinfarct rat hearts. Endocrinology 141, 4592–4599 (2000)PubMed

115.

A. Cittadini, J. Isgaard, M.G. Monti, C. Casaburi, A.D. Di Gianni, R. Serpico, L. Saccà, Growth hormone prolongs survival and attenuates interstitial remodeling in postinfarction heart failure. J. Am. Coll. Cardiol. 41, 2154–2163 (2003)PubMed

116.

R.C. Cuneo, P. Wilmshurst, C. Lowy, G. McGauley, P.H. Sönksen, Cardiac failure responding to growth hormone. Lancet 1, 838–839 (1989)PubMed

117.

A. Frustaci, G.A. Perrone, N. Gentiloni, M.A. Russo, Reversible dilated cardiomyopathy due to growth hormone deficiency. Am. J. Clin. Pathol. 97, 503–511 (1992)PubMed

118.

S. Fazio, D. Sabatini, B. Capaldo, C. Vigorito, A. Giordano, R. Guida, F. Pardo, B. Biondi, L. Sacca, A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N. Engl. J. Med. 334, 809–814 (1996)PubMed

119.

S. Genth-Zotz, R. Zotz, S. Geil, T. Voigtlander, J. Meyer, H. Darius, Recombinant growth hormone therapy in patients with ischemic cardiomyopathy. Effects on hemodynamics, left ventricular function and cardiopulmonary exercise capacity. Circulation 99, 18–21 (1999)PubMed

120.

M. Volterrani, P. Desenzani, R. Lorusso, A. d’Aloia, F. Manelli, A. Giustina, Haemodynamic effects of intravenous growth hormone in congestive heart failure. Lancet 349, 1067–1068 (1997)PubMed

121.

A. Giustina, M. Volterrani, F. Manelli, P. Desenzani, C. Poiesi, R. Lorusso, A. Giordano, Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure. Am. Heart J. 137(6), 1035–1043 (1999)PubMed

122.

S. Adamopoulos, J.T. Parissis, M. Georgiadis, D. Karatzas, I. Paraskevaid, C. Kroupis, G. Karavolias, K. Koniavitou, D.T. Kremastinos, Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy. Am. Heart J. 144, 359–364 (2002)PubMed

123.

R. Napoli, V. Guardasole, M. Matarazzo, E.A. Palmieri, U. Oliviero, S. Fazio, L. Sacca, Growth hormone corrects vascular dysfunction in patients with chronic heart failure. J. Am. Coll. Cardiol. 39, 90–95 (2002)PubMed

124.

K.J. Osterziel, O. Strohm, J. Schuler, M. Friedrich, D. Hanlein, R. Willenbrock, S.D. Anker, P.A. Poole-Wilson, M.B. Ranke, R. Dietz, Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 351, 1233–1237 (1998)PubMed

125.

J. Isgaard, C.H. Bergh, K. Caidahl, M. Lomsky, A. Hjalmarson, B.Å. Bengtsson, A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur. Heart J. 19, 1704–1711 (1998)PubMed

126.

A. Perrot, M.B. Ranke, R. Dietz, K.J. Osterziel, Growth hormone treatment in dilated cardiomyopathy. J. Card. Surg. 16, 127–131 (2001)PubMed

127.

M. Acevedo, R. Corbalán, G. Chamorro, J. Jalil, C. Nazzal, C. Campusano, P. Castro, Administration of growth hormone to patients with advanced cardiac heart failure: effects upon left ventricular function, exercise capacity and neurohormonal status. Int. J. Cardiol. 87, 185–191 (2003)PubMed

128.

H.M. Christensen, C. Kistorp, M. Schou, N. Keller, B. Zerahn, J. Frystyk, P. Schwarz, J. Faber, Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status. Endocrine 43(3), 626–634 (2013)PubMed

129.

N. Mangner, Y. Matsuo, G. Schuler, V. Adams, Cachexia in chronic heart failure: endocrine determinants and treatment perspectives. Endocrine 43, 253–265 (2013)PubMed

130.

S.D. Anker, M. Volterrani, C.D. Pflaum, C.J. Strasburger, K.J. Osterziel, W. Doehner, M.B. Ranke, P.A. Poole-Wilson, A. Giustina, R. Dietz, A.J. Coats, Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J. Am. Coll. Cardiol. 38, 443–452 (2001)PubMed

131.

P. Le Corvoisier, L. Hittinger, P. Chanson, O. Montagne, I. Macquin-Mavier, P. Maison, Cardiac effects of growth hormone treatment in chronic heart failure: a meta-analysis. J. Clin. Endocrinol. Metab. 92, 180–185 (2007)PubMed

132.

L. Sacca, Heart failure as a multiple hormonal deficiency syndrome. Circ Heart Fail. 2, 151–156 (2009)PubMed

133.

E.A. Jankowska, B. Biel, J. Majda, A. Szklarska, M. Lopuszanska, M. Medras, S.D. Anker, W. Banasiak, P.A. Poole-Wilson, P. Ponikowski, Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 114, 1829–1837 (2006)PubMed

134.

M. Volterrani, G. Rosano, F. Iellamo, Testosterone and heart failure. Endocrine 42(2), 272–277 (2012)PubMed

135.

F. Broglio, A. Benso, C. Gottero, L.D. Vito, G. Aimaretti, A. Fubini, E. Arvat, M. Bobbio, E. Ghigo, Patients with dilated cardiomyopathy show reduction of the somatotroph responsiveness to GHRH both alone and combined with arginine. Eur. J. Endocrinol. 142, 157–163 (2000)PubMed

136.

P.E. Kontoleon, M.I. Anastasiou-Nana, P.D. Papapetrou, G. Alexopoulos, V. Ktenas, A.C. Rapti, E.P. Tsagalou, J.N. Nanas, Hormonal profile in patients with congestive heart failure. Int. J. Cardiol. 87, 179–183 (2003)PubMed

137.

S. Watanabe, T. Tamura, K. Ono, H. Horiuchi, T. Kimura, T. Kita, Y. Furukawa, Insulin-like growth factor axis (insulin-like growth factor-I/insulin-like growth factor-binding protein-3) as a prognostic predictor of heart failure: association with adiponectin. Eur. J. Heart Fail. 12, 1214–1222 (2010)PubMed

138.

A. Giustina, R. Lorusso, V. Borghetti, G. Bugari, V. Misitano, O. Alfieri, Impaired spontaneous growth hormone secretion in severe dialated cardiomyopathy. Am. Heart J. 131, 620–622 (1996)PubMed

139.

A. Cittadini, L. Saldamarco, A.M. Marra, M. Arcopinto, G. Carlomagno, M. Imbriaco, D. Del Forno, C. Vigorito, B. Merola, U. Oliviero, S. Fazio, L. Sacca, Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction. J. Clin. Endocrinol. Metab. 94, 3329–3336 (2009)PubMed

Title: GH and the cardiovascular system: an update on a topic at heart
Authors: Jörgen Isgaard
Michele Arcopinto
Kristjan Karason
Antonio Cittadini
Publication date: 01-02-2015
Publisher: Springer US
Published in: Endocrine / Issue 1/2015
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-014-0327-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

GH and the cardiovascular system: an update on a topic at heart

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Identification and validation co-differentially expressed genes with NAFLD and insulin resistance

Normal thyroid-stimulating hormone levels, autoimmune activation, and coronary heart disease risk

Factors associated with glycemic control in adult type 1 diabetes patients treated with insulin pump therapy

Von Hippel-Lindau disease type 2 in a Chinese family with a VHL p.W88X truncation

Intraoperative ultrasonography is useful in surgical management of neck metastases in differentiated thyroid cancers

The effects of sensorial denervation on the ovarian function, by the local administration of capsaicin, depend on the day of the oestrous cycle when the treatment was performed

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page